The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

126–150 of 470

  • SevereFDA (Drugs)·D-771-2015·2015-04-29

    Attix Pharmaceuticals Recalls Magnesium Stearate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Magnesium Stearate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Magnesium Stearate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-818-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitazoxanide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitazoxanide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Nitazoxanide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-883-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rocuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rocuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Rocuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-521-2015·2015-04-29

    Amphotericin B Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Amphotericin B active pharmaceutical ingredient due to potential cross contamination with penicillin during repackaging.

    Product
    Amphotericin B active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-948-2015·2015-04-29

    Valacyclovir HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Valacyclovir HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Valacyclovir HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-815-2015·2015-04-29

    Attix Pharmaceuticals Recalls Neostigmine Methylsulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Neostigmine Methylsulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Neostigmine Methylsulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-789-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methyl 5-Aminolevulinate Hydrochloride Due to Penicillin Contamination Risk

    Attix Pharmaceuticals is recalling Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-946-2015·2015-04-29

    Attix Pharmaceuticals Recalls Uridine-5'Triphosphate Trisodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-681-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flunarizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flunarizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flunarizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-539-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benztropine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benztropine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Benztropine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-554-2015·2015-04-29

    Cabergoline API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cabergoline active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cabergoline active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-680-2015·2015-04-29

    Flumethasone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Flumethasone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flumethasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-719-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-542-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bethanechol Chloride Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Bethanechol Chloride active pharmaceutical ingredient due to potential penicillin cross contamination from inadequate facility separation.

    Product
    Bethanechol Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-747-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lamotrigine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling lamotrigine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lamotrigine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-668-2015·2015-04-29

    Attix Pharmaceuticals Recalls Everolimus API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of everolimus active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Everolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-529-2015·2015-04-29

    Atropine Sulfate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Atropine Sulfate Monohydrate USP active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Atropine Sulfate Monohydrate USP active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-738-2015·2015-04-29

    Attix Pharmaceuticals Recalls Isoxsuprine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Isoxsuprine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Isoxsuprine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-925-2015·2015-04-29

    Attix Pharmaceuticals Recalls Theophylline Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Theophylline Anhydrous active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Theophylline Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-807-2015·2015-04-29

    Attix Pharmaceuticals Recalls Montelukast Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Montelukast Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Montelukast Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-575-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloramphenicol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloramphenicol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Chloramphenicol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-540-2015·2015-04-29

    Attix Pharmaceuticals Recalls Betahistine Dihydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Betahistine Dihydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Betahistine Dihydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-895-2015·2015-04-29

    Simvastatin API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Simvastatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Simvastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-641-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide